Expertise in
3
conditions

Tai-jan S. Chiu

Kaohsiung, KHQ, TW 
Expertise in
3
conditions
Kaohsiung, KHQ, TW 

Overview

Tai-jan Chiu practices practicing medicine in Kaohsiung, Taiwan.

Chiu is highly rated in 3 conditions, according to our data. Their clinical expertise encompasses Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Gastrostomy, and Laryngectomy.

They are actively involved in clinical research, co-authoring 72 peer reviewed articles and participating in 4 clinical trials.

Locations

Kaohsiung, KHQ, Taiwan
Other Locations
Linkou, TPQ, Taiwan
Taoyuan, TNQ, Taiwan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Randomized, Double-blind, Placebo-controlled, 2-arm Phase III Study to Assess Efficacy and Safety of Xevinapant and Radiotherapy Compared to Placebo and Radiotherapy for Demonstrating Improvement of Disease-free Survival in Participants With Resected Squamous Cell Carcinoma of the Head and Neck, Who Are at High Risk for Relapse and Are Ineligible for High-dose Cisplatin (XRAY VISION)
A Randomized, Double-blind, Placebo-controlled, 2-arm Phase III Study to Assess Efficacy and Safety of Xevinapant and Radiotherapy Compared to Placebo and Radiotherapy for Demonstrating Improvement of Disease-free Survival in Participants With Resected Squamous Cell Carcinoma of the Head and Neck, Who Are at High Risk for Relapse and Are Ineligible for High-dose Cisplatin (XRAY VISION)
Enrollment Status: Terminated
Publish Date: February 19, 2026
Intervention Type: Drug, Radiation
Study Phase: Phase 3
A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer
A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer
Enrollment Status: Terminated
Publish Date: November 14, 2023
Intervention Type: Drug
Study Drugs: Bintrafusp Alfa, Gemcitabine, Cisplatin
Study Phase: Phase 2/Phase 3
A Randomized Controlled, Open Label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1+GEM vs GEM Alone in Patients With Measurable Locally Advanced/Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment
A Randomized Controlled, Open Label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1+GEM vs GEM Alone in Patients With Measurable Locally Advanced/Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment
Enrollment Status: Completed
Publish Date: May 06, 2023
Intervention Type: Drug
Study Drugs: EndoTAG-1, Gemcitabine
Study Phase: Phase 3
A Long Term, Open-Label, Multi-Center Study Evaluating Safety and Tolerability of Oxycodone in Patients With Moderate to Severe Cancer Pain
A Long Term, Open-Label, Multi-Center Study Evaluating Safety and Tolerability of Oxycodone in Patients With Moderate to Severe Cancer Pain
Enrollment Status: Completed
Publish Date: March 18, 2020
Intervention Type: Drug
Study Phase: Phase 4
View 3 Less Clinical Trials

72 Total Publications

Response to comment on "Considering the unmeasured impact of 5-fluorouracil dose intensity in the interpretation of optimal initial relative dose intensity of modified FOLFIRINOX".
Response to comment on "Considering the unmeasured impact of 5-fluorouracil dose intensity in the interpretation of optimal initial relative dose intensity of modified FOLFIRINOX".
Journal: Journal of the Formosan Medical Association = Taiwan yi zhi
Published: May 10, 2026

Frequently Asked Questions about Tai-jan S. Chiu

Is Tai-jan S. Chiu a top-rated expert for Pancreatic Ductal Adenocarcinoma?

MediFind is an objective health platform that identifies experts based on real-world data. Tai-jan S. Chiu is classified as an Advanced expert for Pancreatic Ductal Adenocarcinoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Tai-jan S. Chiu participate in research or clinical trials?

Yes. Tai-jan S. Chiu has published 72 articles and abstracts on conditions like Pancreatic Ductal Adenocarcinoma. You can view a list of Tai-jan S. Chiu's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Chiu's expertise for a condition
ConditionClose
      View All 24 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile